Compare Funko Inc (FNKO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Incyte Corporation — how do they compare? Funko Inc trades at $6.23 (market cap $332.33M), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 73.8× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| FNKO | INCY | |
|---|---|---|
Market Cap | $332.33M | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $6.35 | $129.93 |
52-Week Low | $2.65 | $81.61 |
Enterprise Value | $552.98M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.86, down 5.33% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving average support, while oscillators are neutral. Fundamentally, revenue declined to $908.21M in 2025 with a net loss of $67.36M, though recent quarters have beaten EPS estimates. The company maintains a low P/S of 0.35 and appointed a new Chief Commercial Officer in August 2026 to drive growth.
Outlook is cautiously optimistic with improving EBITDA guidance and analyst buy ratings, but risks include persistent net losses, high debt levels, and competitive pressures in the collectibles market. The stock's valuation discount offers potential if profitability strengthens.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
